scholarly article | Q13442814 |
P50 | author | Benjamin Linas | Q56655086 |
P2093 | author name string | Arthur Y Kim | |
Barbara H McGovern | |||
Warren J Ferguson | |||
Robert Trestman | |||
Amy Jo Harzke | |||
Lara B Strick | |||
Arthur Brewer | |||
Anne S Spaulding | |||
Jean C Sullivan | |||
Jeff Dickert | |||
P2860 | cites work | Outcomes of treatment for hepatitis C virus infection by primary care providers | Q24601722 |
Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program | Q24676385 | ||
Prevention and control of infections with hepatitis viruses in correctional settings | Q26151271 | ||
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity | Q30882906 | ||
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings | Q33834958 | ||
Preliminary study of two antiviral agents for hepatitis C genotype 1. | Q34030288 | ||
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. | Q34294185 | ||
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic | Q34554572 | ||
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 | ||
A framework for management of hepatitis C in prisons | Q36479796 | ||
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis | Q36652084 | ||
The economics of hepatitis C virus | Q36681596 | ||
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations | Q36843554 | ||
Screening for HCV infection in jails | Q36983871 | ||
Limited uptake of hepatitis C treatment among injection drug users | Q37238205 | ||
Public health impact of antiviral therapy for hepatitis C in the United States | Q39939298 | ||
End-stage liver disease in a state prison population | Q43039878 | ||
Treatment of chronic hepatitis C in a state correctional facility | Q43042164 | ||
Surprisingly small effect of antiviral treatment in patients with hepatitis C. | Q43889137 | ||
Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. | Q45366817 | ||
Hepatitis C in state correctional facilities | Q46143259 | ||
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. | Q50552857 | ||
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. | Q53118691 | ||
The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997 | Q78447515 | ||
Diversity of release patterns for jail detainees: implications for public health interventions | Q82265286 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Hepatitis C virus | Q708693 |
hepatitis C | Q154869 | ||
P304 | page(s) | 27-35 | |
P577 | publication date | 2013-02-01 | |
P1433 | published in | Topics in antiviral medicine | Q26841872 |
P1476 | title | Impact of new therapeutics for hepatitis C virus infection in incarcerated populations | |
P478 | volume | 21 |
Q35174428 | "Seek, test, treat and retain" for hepatitis C in the United States criminal justice system. |
Q35915999 | A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System |
Q56654943 | A Guide to the Economics of Hepatitis C Virus Cure in 2017 |
Q53572231 | A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. |
Q55154717 | CROI 2018: Highlights of Viral Hepatitis. |
Q30248944 | Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. |
Q35543361 | Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system |
Q64124224 | Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons |
Q51846147 | Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. |
Q34941459 | HCV infected prisoners: should they be still considered a difficult to treat population? |
Q54593526 | Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. |
Q59350307 | Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016 |
Q26785981 | Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment |
Q36862066 | Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons |
Q30377895 | Public health and international drug policy. |
Q35037688 | Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis |
Q33710740 | The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients |
Q35210085 | The need for higher standards in correctional healthcare to improve public health |
Q40039247 | Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health |
Search more.